Products
Lenalidomide is commercially available in the form of hard capsules (Revlimid). It has been approved in many countries since 2007. Generic versions were registered in 2019.
Structure and properties
Lenalidomide (C13H13N3O3, Mr = 259.3 g/mol) is a derivative of thalidomide and exists as a racemate.
Effects
Lenalidomide (ATC L04AX04) has immunomodulatory and antiangiogenic properties.
Indications
- In combination with dexamethasone as a 2nd-line agent for the treatment of patients with multiple myeloma
- For the treatment of patients with transfusion-dependent anemia due to low- or intermediate-risk 1 myelodysplastic syndrome in association with a cytogenetic deletion 5q abnormality with or without other cytogenetic abnormalities.
